In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cyclacel grosses $45mm in private placement

Executive Summary

Cyclacel Pharmaceuticals (cancer therapeutics) grossed $45.3mm through the private placement of 6.4mm units priced at $7.05 apiece (a slight discount to the market average). Each unit consisted of one common share and a warrant to purchase 0.40 shares of common stock. Investors, which included Atlas Master Fund, Visium, SF Capital, Capital Ventures, Magnetar, Federated Kaufman, Deerfield Partners, Baker Biotech, and Red Abbey, also received five-year warrants to purchase an additional 2.57mm common shares at $7 each. The company will use the funds for development of its anticancer candidates seliciclib, sapacitabine, and CYC116.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies